Ryvu Therapeutics Doses First Patient in Phase II REMARK Trial of RVU120 for Lower-Risk MDS
• Ryvu Therapeutics has dosed the first patient in the Phase II REMARK trial, evaluating RVU120 for anemia in lower-risk myelodysplastic syndromes (LR-MDS).
• The REMARK study, an investigator-initiated trial through the EMSCO network, will enroll approximately 40 patients across 25 global clinical sites.
• RVU120, a novel CDK8/19 inhibitor, is being explored as a monotherapy for LR-MDS patients who have exhausted other treatment options.
• The trial's primary goal is to achieve hematologic improvement, with secondary endpoints including transfusion independence and improved hemoglobin levels.
© Copyright 2025. All Rights Reserved by MedPath